Showing 785 articles by Liz Highleyman

Filters Content type: News, About HIV Author: Liz Highleyman

Liz is a medical writer and editor with interests in HIV, hepatitis and cancer. She has contributed conference news reporting for NAM since 2004. Twitter: @LizHighleyman

New & experimental HIV treatments

Dolutegravir is potent but twice-daily works better for integrase-resistant

News
14 October 2011
Hepatitis C treatment

Boceprevir response and resistance differs according to HCV genotype 1 subtype

News
28 July 2011
New & experimental HIV treatments

New integrase inhibitor dolutegravir looks potent and well-tolerated

News
26 July 2011
New & experimental HIV treatments

New NNRTI lersivirine matches efavirenz in phase 2 study

News
22 July 2011
New & experimental HIV treatments

Once-daily elvitegravir matches raltegravir

News
21 July 2011
Neurological & cognitive problems

Cognitive impairment still common but ART reduces risk

News
20 July 2011
New & experimental HIV treatments

Once-daily raltegravir found inferior to twice-daily dosing

News
3 March 2011
New & experimental hepatitis C treatment

Telaprevir works well for people with HIV/HCV co-infection

News
2 March 2011
Bone & joint problems

Does immune reconstitution contribute to ART-related bone loss?

News
2 March 2011
Ageing & HIV

Decreased limb muscle and increased abdominal fat linked to higher mortality in people with HIV

News
2 March 2011
New & experimental HIV treatments

Attachment inhibitor BMS-663068 potent and well-tolerated in early study

News
1 March 2011
New & experimental HIV treatments

Zinc finger gene therapy produces HIV-resistant CD4 T-cells

News
1 March 2011
Neurological & cognitive problems

Neurocognitive impairment linked to prior low CD4 cell count, even if on current suppressive HIV treatment

News
26 July 2010
New & experimental HIV treatments

Good results seen with NRTI-sparing regimens of atazanavir plus newer drug classes

News
26 July 2010
Starting treatment

CASCADE analysis finds antiretroviral treatment benefits are evident below CD4 count of 500, uncertain above this level

News
23 July 2010
New & experimental HIV treatments

Once-daily extended-release nevirapine works as well as twice-daily formulation

News
23 July 2010
New & experimental HIV treatments

Experimental integrase inhibitor GSK-572 shows continued promise

News
23 July 2010
Hepatitis C symptoms & diagnosis

People with HIV/hepatitis C co-infection more likely to develop osteoporosis

News
22 July 2010
Changing treatment

Protease inhibitor to raltegravir switch maintains viral suppression, but NRTI resistance lowers efficacy

News
22 July 2010
Health problems in children & young people

Children with HIV are at risk for metabolic problems and heart muscle dysfunction

News
21 July 2010
Hepatitis C treatment

Does nevirapine improve hepatitis C treatment outcomes in HIV/HCV co-infected individuals?

News
21 July 2010
New & experimental HIV treatments

TBR-652 blocks both CCR5 and CCR2, inhibiting HIV replication and reducing inflammation

News
20 July 2010
Starting treatment

Lopinavir/ritonavir plus raltegravir NRTI-sparing regimen as effective as traditional HAART

News
20 July 2010
The search for a cure

Cure for HIV infection must now be major scientific priority, Vienna AIDS conference hears

News
19 July 2010